Co-Authors
This is a "connection" page, showing publications co-authored by Nicholas Pajewski and Barry Freedman.
Connection Strength
0.665
-
Grams ME, Surapaneni A, Ballew SH, Appel LJ, Boerwinkle E, Boulware LE, Chen TK, Coresh J, Cushman M, Divers J, Gutiérrez OM, Irvin MR, Ix JH, Kopp JB, Kuller LH, Langefeld CD, Lipkowitz MS, Mukamal KJ, Musani SK, Naik RP, Pajewski NM, Peralta CA, Tin A, Wassel CL, Wilson JG, Winkler CA, Young BA, Zakai NA, Freedman BI. APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis. J Am Soc Nephrol. 2019 10; 30(10):2027-2036.
Score: 0.180
-
Freedman BI, Rocco MV, Bates JT, Chonchol M, Hawfield AT, Lash JP, Papademetriou V, Sedor JR, Servilla K, Kimmel PL, Wall BM, Pajewski NM. APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial. Kidney Int Rep. 2017 Jul; 2(4):713-720.
Score: 0.153
-
Freedman BI, Gadegbeku CA, Bryan RN, Palmer ND, Hicks PJ, Ma L, Rocco MV, Smith SC, Xu J, Whitlow CT, Wagner BC, Langefeld CD, Hawfield AT, Bates JT, Lerner AJ, Raj DS, Sadaghiani MS, Toto RD, Wright JT, Bowden DW, Williamson JD, Sink KM, Maldjian JA, Pajewski NM, Divers J. APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. Kidney Int. 2016 08; 90(2):440-449.
Score: 0.145
-
Kurella Tamura M, Gaussoin SA, Pajewski NM, Chelune GJ, Freedman BI, Gure TR, Haley WE, Killeen AA, Oparil S, Rapp SR, Rifkin DE, Supiano M, Williamson JD, Weiner DE. Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial. J Am Soc Nephrol. 2020 09; 31(9):2122-2132.
Score: 0.048
-
Murea M, Geary RL, Edwards MS, Moossavi S, Davis RP, Goldman MP, Hurie J, Williams TK, Velazquez-Ramirez G, Robinson TW, Bagwell B, Tuttle AB, Callahan KE, Rocco MV, Houston DK, Pajewski NM, Divers J, Freedman BI, Williamson JD. A randomized pilot study comparing graft-first to fistula-first strategies in older patients with incident end-stage kidney disease: Clinical rationale and study design. Contemp Clin Trials Commun. 2019 Jun; 14:100357.
Score: 0.044
-
Rocco MV, Chapman A, Chertow GM, Cohen D, Chen J, Cutler JA, Diamond MJ, Freedman BI, Hawfield A, Judd E, Killeen AA, Kirchner K, Lewis CE, Pajewski NM, Wall BM, Yee J. Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. Am J Nephrol. 2016; 44(2):130-40.
Score: 0.037
-
Langefeld CD, Divers J, Pajewski NM, Hawfield AT, Reboussin DM, Bild DE, Kaysen GA, Kimmel PL, Raj DS, Ricardo AC, Wright JT, Sedor JR, Rocco MV, Freedman BI. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int. 2015 Jan; 87(1):169-75.
Score: 0.032
-
Irvin MR, Wineinger NE, Rice TK, Pajewski NM, Kabagambe EK, Gu CC, Pankow J, North KE, Wilk JB, Freedman BI, Franceschini N, Broeckel U, Tiwari HK, Arnett DK. Genome-wide detection of allele specific copy number variation associated with insulin resistance in African Americans from the HyperGEN study. PLoS One. 2011; 6(8):e24052.
Score: 0.026